STOCK TITAN

Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Bicycle Therapeutics plc (BCYC) will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024. The chat will be live-streamed on the company's website, with a replay available afterward.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, at 11 a.m. ET.

A live webcast of the fireside chat will be accessible from the Investor section of the company’s website at www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.

Investors:

Stephanie Yao

SVP, Investor Relations and Corporate Communications

ir@bicycletx.com

857-523-8544



Media:

Argot Partners

Deborah Elson

media@bicycletx.com

212-600-1902

Source: Bicycle Therapeutics plc

FAQ

When will Bicycle Therapeutics participate in the fireside chat?

Bicycle Therapeutics will participate in the fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024.

Where can I watch the live webcast of the fireside chat?

The live webcast of the fireside chat will be accessible from the Investor section of Bicycle Therapeutics' website at www.bicycletherapeutics.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be archived and available following the event.

Bicycle Therapeutics plc American Depositary Shares

NASDAQ:BCYC

BCYC Rankings

BCYC Latest News

BCYC Stock Data

1.38B
46.59M
1.3%
92.35%
4.73%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE